Stockscreener 앱 받기
36.08
6.78%
2.29
시장 영업 전:
36.08
전일 마감가:
$33.79
열려 있는:
$34.01
하루 거래량:
3.43M
Relative Volume:
1.58
시가총액:
$6.82B
수익:
$217.77M
순이익/손실:
$-438.86M
주가수익비율:
-14.97
EPS:
-2.41
순현금흐름:
$-456.33M
1주 성능:
+1.33%
1개월 성능:
+36.20%
6개월 성능:
+37.76%
1년 성능:
-1.53%
1일 변동 폭
$34.01
$36.29
1주일 범위
$33.73
$36.29
52주 변동 폭
$21.62
$41.04
Bridgebio Pharma Inc Stock (BBIO) Company Profile
명칭
Bridgebio Pharma Inc
전화
(650) 391-9740
주소
3160 PORTER DR., PALO ALTO, CA
BBIO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
36.08 | 6.82B | 217.77M | -438.86M | -456.33M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-10-03 | 개시 | Oppenheimer | Perform |
| 2024-09-04 | 개시 | Piper Sandler | Overweight |
| 2024-03-21 | 재개 | Raymond James | Outperform |
| 2024-01-31 | 개시 | BMO Capital Markets | Market Perform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-11-07 | 개시 | Citigroup | Buy |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-07-18 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-04-19 | 개시 | Evercore ISI | Outperform |
| 2023-02-06 | 개시 | Cowen | Outperform |
| 2021-12-27 | 재확인 | Mizuho | Buy |
| 2021-12-27 | 재확인 | SVB Leerink | Outperform |
| 2021-09-10 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-03-22 | 재확인 | Goldman | Buy |
| 2021-02-22 | 재개 | JP Morgan | Overweight |
| 2021-02-09 | 재개 | Goldman | Buy |
| 2021-01-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-10 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-25 | 개시 | BofA/Merrill | Neutral |
| 2020-05-19 | 개시 | BTIG Research | Buy |
| 2020-04-13 | 개시 | H.C. Wainwright | Buy |
| 2020-02-19 | 개시 | Mizuho | Buy |
| 2019-07-26 | 개시 | Raymond James | Outperform |
| 2019-07-22 | 개시 | BMO Capital Markets | Outperform |
| 2019-07-22 | 개시 | Goldman | Buy |
| 2019-07-22 | 개시 | JP Morgan | Overweight |
| 2019-07-22 | 개시 | Jefferies | Buy |
| 2019-07-22 | 개시 | Piper Jaffray | Overweight |
| 2019-07-22 | 개시 | SVB Leerink | Outperform |
모두보기
Bridgebio Pharma Inc 주식(BBIO)의 최신 뉴스
First Week of March 21st Options Trading For BridgeBio Pharma (BBIO) - Nasdaq
Top 4 Health Care Stocks You May Want To Dump In Q1 - Benzinga
Moss Adams Wealth Advisors LLC Acquires New Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Short Interest Up 12.7% in December - MarketBeat
BridgeBio Pharma (NASDAQ:BBIO) Stock Price Up 6.6%Time to Buy? - MarketBeat
Hypoparathyroidism Market Anticipated to Expand Rapidly During 2024-2034, Says DelveInsight | Bridgebio/Calcil ytix Therapeutics, Ascendis Pharma, EnteraBio, Shire - Barchart
Hypoparathyroidism Market Anticipated to Expand Rapidly - openPR
Is BridgeBio Pharma, Inc. (BBIO) Among Tuesday’s Top Gainers? - MSN
Strength Seen in BridgeBio Pharma (BBIO): Can Its 16.0% Jump Turn into More Strength? - MSN
BridgeBio Pharma Is A Buy On Dips After Attruby’s FDA Approval (NASDAQ:BBIO) - Seeking Alpha
Why BridgeBio Pharma (BBIO) Led the Monday Upsurge? - MSN
Epidermolysis Bullosa Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and Key Companies Involved by DelveInsight | RegeneRx Biopharma, BridgeBio Pharma, Berg Pharma, Holostem Terapie - The Globe and Mail
BridgeBio Pharma Stock Earns 87 RS Rating - Yahoo! Voices
BridgeBio Pharma (NASDAQ:BBIO) Shares Up 6.6%What's Next? - MarketBeat
BridgeBio reports strong Attruby launch, advances phase 3 trials By Investing.com - Investing.com Australia
BridgeBio Pharma Reports Strong Drug Uptake and Trial Progress - TipRanks
BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps. - Yahoo! Voices
BridgeBio Pharma (NASDAQ:BBIO) Sees Large Volume IncreaseHere's Why - MarketBeat
Investors Purchase High Volume of BridgeBio Pharma Call Options (NASDAQ:BBIO) - MarketBeat
BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones - Yahoo Finance
BridgeBio trades higher on pipeline progress By Investing.com - Investing.com Nigeria
BridgeBio Pharma in Strong Cash Position to Launch Attruby -January 13, 2025 at 12:02 pm EST - Marketscreener.com
BridgeBio trades higher on pipeline progress - Investing.com
BridgeBio Pharma in Strong Cash Position to Launch Attruby - MarketWatch
BridgeBio reports strong Attruby launch, advances phase 3 trials - Investing.com
BridgeBio's Attruby Gains Momentum with 430 Prescriptions as Three Phase 3 Trials Hit Key Milestone - StockTitan
BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Popularity With Investors Is Under Threat From Overpricing - Simply Wall St
Rare Endocrinology and Metabolic Disorders Market Analysis: Emerging Trends and Future Outlook of Hypophosphatasia, Congenital Adrenal Hyperplasia, and Severe Hypertriglyceridemia | DelveInsight - GlobeNewswire Inc.
BridgeBio Oncology Therapeutics (BBOT) Granted U.S. FDA Fast Track Designation for BBO-8520 for KRAS - Business Wire
BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference - The Manila Times
BridgeBio Pharma CEO to Present at J.P. Morgan Healthcare Conference 2024 - StockTitan
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Objective long/short (BBIO) Report - Stock Traders Daily
Is This Biotech Stock With 150% Upside a Buy Now? - MSN
Astrazeneca Plc ADR (AZN-Q) QuotePress Release - The Globe and Mail
Pfizer Inc (PFE-N) QuotePress Release - The Globe and Mail
Is This Biotech Stock With 150% Upside A Buy Now? - Barchart
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Bought by Principal Financial Group Inc. - MarketBeat
BridgeBio price target raised to $50 from $45 at Evercore ISI - Yahoo Finance
BridgeBio Pharma (NASDAQ:BBIO) Stock Price Expected to Rise, Evercore ISI Analyst Says - MarketBeat
Bridgebio’s Attruby FDA nod boosts stock; 10 November approvals - BioWorld Online
How To Trade (BBIO) - Stock Traders Daily
BridgeBio Oncology Therapeutics (BBOT) to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025 - BioSpace
Geode Capital Management LLC Purchases 123,540 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Bridgebio Pharma Inc (BBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.81%
자본화:
|
볼륨(24시간):